EA201890578A1 - Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли - Google Patents

Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли

Info

Publication number
EA201890578A1
EA201890578A1 EA201890578A EA201890578A EA201890578A1 EA 201890578 A1 EA201890578 A1 EA 201890578A1 EA 201890578 A EA201890578 A EA 201890578A EA 201890578 A EA201890578 A EA 201890578A EA 201890578 A1 EA201890578 A1 EA 201890578A1
Authority
EA
Eurasian Patent Office
Prior art keywords
post
traumatic headache
persistent
prevention
reduction
Prior art date
Application number
EA201890578A
Other languages
English (en)
Inventor
Марсело Бигал
Original Assignee
Тева Фармасьютикалз Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикалз Интернэшнл Гмбх filed Critical Тева Фармасьютикалз Интернэшнл Гмбх
Publication of EA201890578A1 publication Critical patent/EA201890578A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В настоящем документе предложены способы лечения или снижения частоты возникновения посттравматической головной боли и/или по меньшей мере одного вторичного симптома, ассоциированного с посттравматической головной болью у субъекта, включающие введение указанному субъекту моноклонального антитела, которое модулирует путь CGRP. Также предложены композиции для применения в описанных способах. Также описаны антагонистическое антитело G1 и происходящие из G1 антитела, направленные на CGRP.
EA201890578A 2015-09-24 2016-09-23 Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли EA201890578A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232343P 2015-09-24 2015-09-24
US201662375825P 2016-08-16 2016-08-16
PCT/IB2016/055720 WO2017051385A1 (en) 2015-09-24 2016-09-23 Preventing, treating, and reducing (persistent) post-traumatic headache

Publications (1)

Publication Number Publication Date
EA201890578A1 true EA201890578A1 (ru) 2018-12-28

Family

ID=57121460

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890578A EA201890578A1 (ru) 2015-09-24 2016-09-23 Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли

Country Status (13)

Country Link
US (3) US20170088612A1 (ru)
EP (1) EP3353202B1 (ru)
JP (2) JP2018532728A (ru)
KR (2) KR20180058777A (ru)
CN (1) CN108473560A (ru)
AU (2) AU2016325738A1 (ru)
CA (1) CA2999809A1 (ru)
EA (1) EA201890578A1 (ru)
ES (1) ES2846878T3 (ru)
HK (2) HK1258385A1 (ru)
IL (1) IL258008A (ru)
MX (1) MX2018003713A (ru)
WO (1) WO2017051385A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
ES2893073T3 (es) 2011-05-20 2022-02-07 H Lundbeck As Composiciones anti CGRP y uso de las mismas
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US20190225689A1 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
US20200383983A1 (en) * 2019-04-18 2020-12-10 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
MX2022015230A (es) * 2020-06-03 2023-01-04 Miotox Llc Metodos y usos zonal y dirigido para el tratamiento de un trastorno de migra?a.
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704770D0 (sv) * 1997-12-19 1997-12-19 Astra Ab New use
ME00419B (me) * 2005-11-14 2011-10-10 Rinat Neuroscience Corp Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja
ES2893073T3 (es) * 2011-05-20 2022-02-07 H Lundbeck As Composiciones anti CGRP y uso de las mismas
SG11201403769YA (en) * 2012-01-10 2014-07-30 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo

Also Published As

Publication number Publication date
AU2016325738A1 (en) 2018-04-12
EP3353202B1 (en) 2020-11-04
EP3353202A1 (en) 2018-08-01
JP2018532728A (ja) 2018-11-08
ES2846878T3 (es) 2021-07-30
WO2017051385A1 (en) 2017-03-30
CA2999809A1 (en) 2017-03-30
IL258008A (en) 2018-06-28
HK1258474A1 (zh) 2019-11-15
KR20180058777A (ko) 2018-06-01
KR20200035163A (ko) 2020-04-01
MX2018003713A (es) 2018-08-15
HK1258385A1 (zh) 2019-11-08
US20200148761A1 (en) 2020-05-14
CN108473560A (zh) 2018-08-31
JP2020002172A (ja) 2020-01-09
US20220048986A1 (en) 2022-02-17
US20170088612A1 (en) 2017-03-30
AU2019261726A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
MX2019003337A (es) Tratamiento para migraña refractaria.
MX2019003338A (es) Tratamiento de cefalea en racimos.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
MY195110A (en) Antibodies to PD-1 and uses Thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MX370848B (es) Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
JO3701B1 (ar) مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
MX2018009680A (es) Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.